Gene Biotherapeutics (CRXM) 10-Q 18 Jun 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Jun. 18, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	CRXM
Entity Registrant Name	Taxus Cardium Pharmaceuticals Group Inc.
Entity Central Index Key	772320
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		12,775,044

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$8,866	$216,733
Prepaid expenses and other assets	218,288	202,957
Total current assets	227,154	419,690
Property and equipment, net	13,327	16,414
Investments	300,000	300,000
Other long term assets	9,989	9,989
Total assets	550,470	746,093
Current liabilities:
Accounts payable	1,349,826	1,204,302
Accrued liabilities	668,231	535,251
Advances from related party - officer	706,284	688,433
Total current liabilities	2,724,341	2,427,986
Total liabilities	2,724,341	2,427,986
Commitments and contingencies
Stockholders' deficit:
Common stock, $0.0001 par value; 200,000,000 shares authorized; issued and outstanding 12,775,044 at March 31, 2015 and December 31, 2014, respectively	1,278	1,278
Additional paid-in capital	109,268,430	109,150,983
Accumulated Deficit	-111,443,579	-110,834,154
Total stockholders' deficit	-2,173,871	-1,681,893
Total liabilities and stockholders' deficit	550,470	746,093
Series A Convertible Preferred Stock [Member]
Stockholders' deficit:
Series A Convertible Preferred stock, $0.0001 par value; 40,000,000 shares authorized; issued and outstanding 1,176 at March 31, 2015 and December 31, 2014, respectively, with liquidation preferences of $1,000	$0	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	12,775,044	12,775,044
Common stock, shares outstanding	12,775,044	12,775,044
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred stock, par value	$0.00	$0.00
Series A Convertible Preferred stock, shares authorized	40,000,000	40,000,000
Series A Convertible Preferred stock, shares issued	1,176	1,176
Series A Convertible Preferred stock, shares outstanding	1,176	1,176
Series A Convertible Preferred stock, liquidation preference value	$1,000	$1,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating expenses
Research and development	$78,562	$243,544
Selling, general and administrative	529,695	1,194,945
Total operating expenses	608,257	1,438,489
Loss from operations	-608,257	-1,438,489
Interest expense	1,168
Net loss	($609,425)	($1,438,489)
Net loss per share - Basic and diluted
Net loss per share - Basic and diluted	($0.05)	($0.16)
Weighted average common shares outstanding	12,737,875	9,037,771

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash Flows From Operating Activities
Net loss	($609,425)	($1,438,489)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	3,087	3,556
Provision for obsolete inventory		25,000
Stock based compensation expense	117,447	506,165
Changes in operating assets and liabilities
Prepaid expenses and other assets	-15,331	-129,670
Deposits		60,000
Payables advance from officer	17,851	417,484
Accounts payable	145,524	110,819
Accrued liabilities	132,980	128,638
Net cash used in operating activities	-207,867	-316,497
Cash Flows From Financing Activities
Net Proceeds from sales of preferred and common stock		457,500
Net cash provided by financing activities		457,500
Net increase (decrease) in cash	-207,867	141,003
Cash and cash equivalents at beginning of period	216,733	22,489
Cash and cash equivalents at end of period	8,866	163,492
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	1,168
Non-Cash Activity:
Warrants issued in settlement of Accounts Payable		$75,000

Organization_and_Liquidity

Organization and Liquidity	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization and Liquidity	Note 1. Organization and Liquidity
	Organization
	Taxus Cardium Pharmaceuticals Group, Inc. (the “Company,” or “Cardium,”) was incorporated in Delaware in December 2003. The Company is a regenerative medicine biotechnology company focused on the development of advanced regenerative therapeutics designed to promote the activation and growth of (1) microvascular circulation to enhance perfusion of ischemic cardiac tissue as a potential treatment for heart disease; and (2) granulation tissue as a treatment for chronic non-healing wounds. The Company has a commercial FDA-cleared wound care product, a late clinical stage cardiovascular gene therapy product candidate and corresponding technology platforms as outlined below. The Company also owns LifeAgain Insurance Solutions, Inc., a medical analytics business and holds an investment interest in Healthy Brands Collective, a health products company.
	Based on the Company’s business strategy of partnering or otherwise monetizing products and product candidates with third party commercialization partners, two subsidiaries have been formed to coordinate the independent monetization and funding activities of its core products and technologies. The Angionetics Inc. subsidiary will focus on the late-stage clinical development and commercialization of the Company’s Generx ® angiogenic gene therapy product candidate, and the Activation Therapeutics, Inc. subsidiary will focus on the commercialization of the Excellagen ® FDA-cleared wound care product and the joint clinical development of Excellagen product line extensions as an advanced biologic delivery platform for new and innovative wound healing therapeutics.
	During 2013, the Company completed the initial product development of LifeAgain™, a medical analytics and social media-driven enabled e-commerce platform that is focused on the development, marketing and direct sales of new and innovative survivable risk, multi-year, non-convertible level term life insurance programs and other insurance products, that are currently non-accessible and unaffordable for certain sub-groups of highly motivated buyers considered “uninsurable” based on traditional underwriting standards by U.S. life insurance companies. The Company released the first product aimed at individuals with prostate cancer in 2013. LifeAgain Insurance Solutions, Inc. is operated as a wholly-owned subsidiary of Cardium.
	The Company’s business is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address significant unmet medical needs, and having definable pathways to commercialization. The Company intends to consider various corporate development transactions designed to place its product candidates into larger organizations or with partners having existing commercialization, sales and marketing resources, and a need for innovative products. Such transactions could involve the sale, partnering or other monetization of particular product opportunities or businesses.
	The Company has yet to generate positive cash flows from operations, and is essentially dependent on debt and equity funding to finance its operations.
	Liquidity and Going Concern
	As of March 31, 2015, the Company had $8,866 in cash and cash equivalents. Its working capital deficit at March 31, 2015 was approximately $2,497,187.
	The Company anticipates that negative cash flow from operations will continue for the foreseeable future. The Company does not have any unused credit facilities. As long as any shares of the Company’s Series A Convertible Preferred Stock are outstanding, the Company has agreed that it will not, without the consent of the holders of two-thirds of the Series A Convertible Preferred Stock, incur indebtedness other than specified “Permitted Indebtedness”, or incur any liens other than specified “Permitted Liens”.
	The Company intends to secure additional working capital through sales of debt and equity securities to finance our operations, or the sale of certain equity interests in the Company businesses, technology platforms, products or product candidates and licensing agreements covering the marketing and sale of Excellagen and Generx in certain geographic markets and regions.
	On April 4, 2015, the Company entered into a binding term sheet with Shenzhen Qianhai Taxus Industry Capital Management Co., Ltd (“Shenzhen Qianhai Taxus”), as lead investor, to purchase an equity stake in Angionetics Inc., Under the terms of the agreement, Shenzhen Qianhai Taxus agreed to acquire 15% of Angionetics’ outstanding common stock for an aggregate purchase price of $3,000,000, payable in three tranches. As of the date of this report Shenzhen Qianhai Taxus has paid $600,000 of the financing. See “Note 7—Subsequent Events” below.
	The Company’s principal business objectives are to advance the independent monetization and funding activities of its core products and technologies, with the Angionetics Inc. subsidiary being focused on the Generx angiogenic gene therapy product candidate, and the Activation Therapeutics, Inc. subsidiary being focused on the Excellagen FDA-cleared wound care product and the joint clinical development of Excellagen product line extensions as an advanced biologic delivery platform for new and innovative wound healing therapeutics, and/or to complete alterative corporate transactions. If the Company fails to conclude such a transaction in a timely manner or alternatively fails to generate sufficient cash from financing activities, it will not generate sufficient cash flows to cover its operating expenses.
	The Company’s history of recurring losses and uncertainties as to whether the Company’s operations will become profitable raise substantial doubt about its ability to continue as a going concern. The condensed consolidated financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2—Summary of Significant Accounting Policies
	Basis of Presentation
	The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of our management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2015 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future period.
	These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Our accounting policies are described in the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2014, and updated, as necessary, in this Quarterly Report on Form 10-Q.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates include reserve for inventory, and valuing options and warrants using option pricing models.
	Fair Value of Financial Instruments
	The carrying amounts of cash and cash equivalents, accounts receivable, inventories, accounts payable, and accrued liabilities approximate fair value due to the short term maturities of these instruments.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Taxus Cardium Pharmaceuticals Group, Inc. and its consolidated subsidiaries, Angionetics Inc., Activation Therapeutics, Inc. (formerly Tissue Repair Company), To Go Brands, Inc. and LifeAgain Insurance Solutions, Inc.. All significant inter-company transactions and balances have been eliminated in consolidation.
	Preferred Stock
	The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
	Research and Development
	In accordance with ASC Topic 730 (FASB Accounting Standard Codification) research and development costs are expensed as incurred. Research and development expenses consist of purchased technology, purchased research and development rights and outside services for research and development activities associated with product development. In accordance with ASC Topic 730, the cost to purchase such technology and research and development rights are required to be charged to expense if there is currently no alternative future use for this technology and, therefore, no separate economic value.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not to be sustained upon examination.
	Common Stock Purchase Warrants
	The Company accounts for common stock purchase warrants issued in connection with capital financing transactions in accordance with the provisions of ASC Topic 815. Based upon the provisions of ASC Topic 815, the Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).
	Loss Per Common Share
	The Company computes loss per share, in accordance with ASC Topic 260 which requires dual presentation of basic and diluted earnings per share.
	Basic income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants.
	As of March 31, 2015, potentially dilutive securities consist of outstanding stock options and warrants to acquire 3,793,492 shares of our common stock. As of March 31, 2014, potentially dilutive securities consisted of outstanding stock options and warrants to acquire 2,500,165 shares of our common stock. These potentially dilutive securities were not included in the calculation of loss per common share for the three months ended March 31, 2015 or 2014 because their effect would be anti-dilutive.
	Stock-Based Compensation
	Stock-based compensation costs are recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the award.
	Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:
		For the Three Months Ended
		March 31,
		2015		2014
	Research and development	$	—	$	51,409
	General and administrative		117,447		454,756
	Total stock-based compensation	$	117,447	$	506,165
	Investments
	The Company periodically reviews the carrying amount of its investment in Cell-nique to determine whether the value is impaired or a write down may be necessary for an other than temporary decline in value. During the three months ended March 31, 2015 no impairment was recorded.
	Recent Accounting Pronouncements
	Management continually evaluates the potential impact, if any, of all recent accounting pronouncements on our condensed consolidated financial statements or related disclosures and, if significant, makes the appropriate disclosures required by such new accounting pronouncements.

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Note 3—Accrued Liabilities
	Accrued Liabilities consisted of the following:
		March 31,		December 31,
		2015		2014
	Payroll and benefits	$	535,992	$	465,512
	Technology Fees		62,500		—
	Other		69,739		69,739
	Total	$	668,231	$	535,251

Advances_From_Related_Party_Of

Advances From Related Party - Officer	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Advances From Related Party - Officer	Note 4—Advances From Related Party - Officer
	Officers of the Company occasionally incur or advance expenses on behalf of the Company, which are subsequently reimbursed to the officers along with any associated costs. As of March 31, 2015 and December 31, 2014, approximately $706,284 and $688,433, respectively, in Company expenses incurred in the ordinary course of business that have been paid by or with cash advanced by the Company’s Chief Executive Officer.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	Note 5—Stockholders’ Equity
	Stock Options and Other Equity Compensation Plans
	The Company has an equity incentive plan that was established in 2005 under which 283,058 shares of the Company’s common stock have been reserved for issuance to employees, non-employee directors and consultants of the Company.
	At March 31, 2015 the following shares were outstanding and available for future issuance under the option plan:
	Plan	Shares Outstanding			Shares Available
					for Issuance
	2005 Equity Incentive Plan		108,250			174,808
	On February 28, 2014, outside of the 2005 Equity Incentive Plan, the Company issued 1,457,100 common stock warrants to directors, officers and chief medical advisor. The warrants were approved by the Board of Directors, have a ten year term and an exercise price of $0.80 per share, which represented a 57% premium to the closing stock price on the date of issuance.
	On March 23, 2015, outside of the 2005 Equity Incentive Plan, the Company issued 1,125,000 common stock warrants to directors, officers and chief medical advisor. The warrants were approved by the Board of Directors, have a ten year term and an exercise price of $0.60 per share, which represented a 216% premium to the closing stock price on the date of issuance. The warrants had a fair value of $0.10 per share and vested immediately.
	On March 23, 2015 the Company issued 10,000 non-qualified stock options to directors. The options were approved by the Board of Directors, have a seven year term and an exercise price of $0.19 per share, which equaled the closing stock price on the date of issuance.
	The following is a summary of stock option and warrant activity under the Company’s equity incentive plan and warrants issued outside of the plan to employees and consultants, during the three months ended March 31, 2015:
		Number of			Weighted		Weighted
		Options or			Average		Average
		Warrants			Exercise		Remaining
					Price		Contractual
							Life
							(in years)
	Balance outstanding, December 31, 2014		1,914,906		$	2.44		8.74
	Granted		1,135,000			0.6		9.98
	Exercised		—			—		—
	Cancelled		—			—		—
	Cancelled (unvested)		—			—		—
	Expired (vested)		(5,750	)		14.8		—
	Balance outstanding, March 31, 2015		3,044,156		$	1.73		9.05
	Balance exercisable, March 31, 2015		3,032,656		$	1.74		9.06
	As of March 31, 2015 there was no intrinsic value to the outstanding and exercisable options and warrants.
	Warrants
	The following table summarizes warrant activity issued in connection with financing transactions for the three months ended March 31, 2015:
		Number of			Weighted		Weighted
		Warrants			Average		Average
					Exercise		Remaining
					Price		Contractual
							Life
							(in years)
	Balance outstanding, December 31, 2014		873,336		$	17.79		1.06
	Warrants issued
	Warrants exercised
	Warrants expired		(112,500	)		35.4
	Warrants cancelled
	Balance outstanding, March 31, 2015		760,836		$	15.19		0.94
	Warrants exercisable at March 31, 2015		760,836		$	15.19		0.94
	As of March 31, 2015 there was no intrinsic value to the outstanding and exercisable warrants.

Commitments_and_contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 6—Commitments and contingencies
	The Company in the course of its business, is routinely involved in proceedings such as disputes involving goods or services provided by various third parties to Cardium or its subsidiaries, which it does not consider likely to be material to the technology it develops or licenses, or the products it develops for commercialization, but which can nevertheless result in costs and diversions of resources to pursue and resolve. For example, in October 2014 the Company received a complaint filed by BioRASI LLC in Broward County, Florida, seeking payments of approximately $0.5 million alledgedly owed for services that BioRASI provided in connection with the Company’s clinical trial conducted in the Russian Federation. The Company is defending the action and has filed counterclaims.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 7—Subsequent Events
	The Company has evaluated events that occurred subsequent to March 31, 2015 and through the date the condensed consolidated financial statements were issued.
	Resignation of Chief Financial Officer
	On April 3, 2015, Dennis Mulroy resigned as the Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc. and from all other offices with the Company. Mr. Mulroy resigned to pursue other opportunities and his departure was not due to any dispute or disagreement with the Company. He did not receive any severance payments under his employment agreement in connection with his departure.
	Co-Development and Distribution Agreement with Dr. Reddy’s Laboratories Ltd.
	On April 6, 2015, the Company entered into a term sheet with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) covering the co-development, marketing and sales of the Generx [Ad5FGF-4] angiogenic microvascular gene therapy Phase 3 product candidate for patients with refractory angina and myocardial ischemia due to cardiac microvascular insufficiency. The terms sheet outlines the principle agreements between the parties and is binding, but is expected to be superseded by a definitive agreement with more detailed terms.
	The term sheet grants Dr. Reddy’s Laboratories an exclusive license to market and sell Generx in Russia, the Commonwealth of Independent States (CIS), Venezuela, Vietnam and Myanmar (the “Licensed Territories”) for a period of ten years with two five-year renewal options. Dr. Reddy’s Laboratories’ Russian-based business unit currently markets and sells prescription products in Russia. The term sheet grants Dr. Reddy’s Laboratories a right of first negotiation for the license rights to market and sell Generx in up to 32 other countries in Latin America and the Association of Southeast Asian Nations. The Company retains full commercialization rights for North America, Europe, Japan, China, the Middle East, and Africa.
	As co-development partner, Dr. Reddy’s Laboratories will assist with physician and hospital relationships as well as patient recruitment to accelerate completion of international Phase 3 ASPIRE clinical study in Russia. Dr. Reddy’s Laboratories’ Russian-based business unit markets and sells prescription products through its team of medical representatives and managers who promote the products to physicians across Russia. It has also agreed to assist with product registrations and regulatory compliance with local country health authorities in other jurisdictions in the Licensed Territories. Upon registration of Generx® in Russia, Taxus Cardium and Dr. Reddy’s Laboratories have agreed to share costs for a planned Phase 4 post-marketing clinical study, intended to expand the medical indications for which the product can be used.
	The term sheet requires Dr. Reddy’s Laboratories to pay upfront licensing fees on execution of the definitive agreement and upon registration of the Generx product in Russia. The Company will retain control over the manufacturing of Generx and will supply it to Dr. Reddy’s Laboratories on a cost-plus basis. Dr. Reddy’s will pay royalties on net sales of Generx, with the percentage varying based on the degree of market penetration for the product in the relevant territory.
	Formation of Angionetics Inc.
	In April 2015, the Company formed a new subsidiary Angionetics Inc., a Delaware corporation, for the purpose of continuing the work of the Company’s Cardium Therapeutics business. Angionetics Inc. is focused on the Phase 3 clinical development and commercialization of Generex, the Company’s angiogenic gene therapy product candidate for the treatment of refractory angina and myocardial ischemia due to cardiac microvascular insufficiency.
	Angionetics Financing Agreement
	On April 8, 2015, the Company entered into a binding term sheet with Shenzhen Qianhai Taxus Industry Capital Management Co., Ltd (“Shenzhen Qianhai Taxus”), as lead investor, to purchase an equity stake in Angionetics Inc.
	Under the term sheet, Shenzhen Qianhai Taxus agreed to acquire 15% of Angionetic’s outstanding common stock, from the Company, for an aggregate purchase price of $3,000,000 or 600,000 shares at $5 per share, payable in three tranches. As of the date of this report Shenzhen Qianhai Taxus has paid $600,000 of the financing. On completion of the purchase, the Company has agreed to grant Shenzhen Qianhai Taxus a right of first negotiation for exclusive license agreements for certain Asian markets to register, market and sell the Generx product candidate, Excellagen, and LifeAgain.
	The agreement contemplates that this initial funding is a bridge investment to a separate larger financing to be conducted by Angionetics, Inc., including a potential registration and public offering of securities. The terms provide for the Company to gross up Shenzhen Qianhai Taxus’ shares to equate to a 15% interest in Angionetics, Inc. following any such public offering. It also provides for certain registration rights for the shares purchased by Shenzhen Qianhai Taxus.
	Shenzhen Qianhai Taxus is an affiliate of Shanxi Taxus Pharmaceuticals Co., Ltd. which holds approximately 27.5% of Cardium’s outstanding common stock as a result of a Stock Purchase Agreement dated February 21, 2014. In connection with that transaction, the Company granted Shanxi Taxus Pharmaceuticals Co., Ltd. the right to appoint two members to our Board of Directors. Mr. Jiayue Jhang, one of the appointed members of our Board of Directors who serves as our Chairman, is the Chairman of Shenzhen Qianhai Taxus and Shanxi Taxus Pharmaceuticals Co., Ltd.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of our management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2015 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future period.
	These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Our accounting policies are described in the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2014, and updated, as necessary, in this Quarterly Report on Form 10-Q.
Estimates	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates include reserve for inventory, and valuing options and warrants using option pricing models.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying amounts of cash and cash equivalents, accounts receivable, inventories, accounts payable, and accrued liabilities approximate fair value due to the short term maturities of these instruments.
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of Taxus Cardium Pharmaceuticals Group, Inc. and its consolidated subsidiaries, Angionetics Inc., Activation Therapeutics, Inc. (formerly Tissue Repair Company), To Go Brands, Inc. and LifeAgain Insurance Solutions, Inc.. All significant inter-company transactions and balances have been eliminated in consolidation.
Preferred Stock	Preferred Stock
	The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
Research and Development	Research and Development
	In accordance with ASC Topic 730 (FASB Accounting Standard Codification) research and development costs are expensed as incurred. Research and development expenses consist of purchased technology, purchased research and development rights and outside services for research and development activities associated with product development. In accordance with ASC Topic 730, the cost to purchase such technology and research and development rights are required to be charged to expense if there is currently no alternative future use for this technology and, therefore, no separate economic value.
Income Taxes	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not to be sustained upon examination.
Common Stock Purchase Warrants	Common Stock Purchase Warrants
	The Company accounts for common stock purchase warrants issued in connection with capital financing transactions in accordance with the provisions of ASC Topic 815. Based upon the provisions of ASC Topic 815, the Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).
Loss Per Common Share	Loss Per Common Share
	The Company computes loss per share, in accordance with ASC Topic 260 which requires dual presentation of basic and diluted earnings per share.
	Basic income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants.
	As of March 31, 2015, potentially dilutive securities consist of outstanding stock options and warrants to acquire 3,793,492 shares of our common stock. As of March 31, 2014, potentially dilutive securities consisted of outstanding stock options and warrants to acquire 2,500,165 shares of our common stock. These potentially dilutive securities were not included in the calculation of loss per common share for the three months ended March 31, 2015 or 2014 because their effect would be anti-dilutive.
Stock-Based Compensation	Stock-Based Compensation
	Stock-based compensation costs are recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the award.
	Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:
		For the Three Months Ended
		March 31,
		2015		2014
	Research and development	$	—	$	51,409
	General and administrative		117,447		454,756
	Total stock-based compensation	$	117,447	$	506,165
Investments	Investments
	The Company periodically reviews the carrying amount of its investment in Cell-nique to determine whether the value is impaired or a write down may be necessary for an other than temporary decline in value. During the three months ended March 31, 2015 no impairment was recorded.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	Management continually evaluates the potential impact, if any, of all recent accounting pronouncements on our condensed consolidated financial statements or related disclosures and, if significant, makes the appropriate disclosures required by such new accounting pronouncements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses	Total stock-based compensation expense included in the condensed consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:
		For the Three Months Ended
		March 31,
		2015		2014
	Research and development	$	—	$	51,409
	General and administrative		117,447		454,756
	Total stock-based compensation	$	117,447	$	506,165

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Summary of Accrued Liabilities	Accrued Liabilities consisted of the following:
		March 31,		December 31,
		2015		2014
	Payroll and benefits	$	535,992	$	465,512
	Technology Fees		62,500		—
	Other		69,739		69,739
	Total	$	668,231	$	535,251

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Schedule of Available Outstanding Shares for Future Issuance	At March 31, 2015 the following shares were outstanding and available for future issuance under the option plan:
	Plan	Shares Outstanding			Shares Available
					for Issuance
	2005 Equity Incentive Plan		108,250			174,808
Summary of Stock Option Activity under Equity Incentive Plan and Warrants Issued Outside Plan	The following is a summary of stock option and warrant activity under the Company’s equity incentive plan and warrants issued outside of the plan to employees and consultants, during the three months ended March 31, 2015:
		Number of			Weighted		Weighted
		Options or			Average		Average
		Warrants			Exercise		Remaining
					Price		Contractual
							Life
							(in years)
	Balance outstanding, December 31, 2014		1,914,906		$	2.44		8.74
	Granted		1,135,000			0.6		9.98
	Exercised		—			—		—
	Cancelled		—			—		—
	Cancelled (unvested)		—			—		—
	Expired (vested)		(5,750	)		14.8		—
	Balance outstanding, March 31, 2015		3,044,156		$	1.73		9.05
	Balance exercisable, March 31, 2015		3,032,656		$	1.74		9.06
Summary of Warrant Activity	The following table summarizes warrant activity issued in connection with financing transactions for the three months ended March 31, 2015:
		Number of			Weighted		Weighted
		Warrants			Average		Average
					Exercise		Remaining
					Price		Contractual
							Life
							(in years)
	Balance outstanding, December 31, 2014		873,336		$	17.79		1.06
	Warrants issued
	Warrants exercised
	Warrants expired		(112,500	)		35.4
	Warrants cancelled
	Balance outstanding, March 31, 2015		760,836		$	15.19		0.94
	Warrants exercisable at March 31, 2015		760,836		$	15.19		0.94

Organization_and_Liquidity_Add

Organization and Liquidity - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Apr. 08, 2015	Apr. 04, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
	Subsidiaries	Tranches	Tranches
Organization, Nature Of Operations And Liquidity [Line Items]
Incorporation date	22-Dec-03
Number of subsidiaries formed	2
Cash and cash equivalents	$8,866			$216,733	$163,492	$22,489
Working capital deficit	2,497,187
Majority of shareholders' consent to incur indebtedness other than specified permitted indebtedness	Two-thirds
Shenzhen Qianhai Taxus [Member]
Organization, Nature Of Operations And Liquidity [Line Items]
Business acquisition, date of agreement	4-Apr-15
Subsequent Events [Member] | Shenzhen Qianhai Taxus [Member]
Organization, Nature Of Operations And Liquidity [Line Items]
Acquired percentage of outstanding common stock		15.00%	15.00%
Business acquisition, purchase price		3,000,000	3,000,000
Number of tranches payable		3	3
Payment for business acquisition		$600,000	$600,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Outstanding stock options and warrants	3,793,492	2,500,165
Dilutive securities not included in calculation of loss per common share	0	0
Impairment loss on investment	$0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$117,447	$506,165
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation		51,409
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$117,447	$454,756

Accrued_Liabilities_Summary_of

Accrued Liabilities - Summary of Accrued Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Payroll and benefits	$535,992	$465,512
Technology Fees	62,500
Other	69,739	69,739
Total	$668,231	$535,251

Advances_From_Related_Party_Of1

Advances From Related Party - Officer - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Related party transaction, expenses paid by chief executive officer	$706,284	$688,433

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended
	Mar. 23, 2015	Feb. 28, 2014	Mar. 31, 2015
Stockholders Equity [Line Items]
Intrinsic value of options outstanding			$0
Intrinsic value of options exercisable			0
Warrants [Member]
Stockholders Equity [Line Items]
Intrinsic value of options outstanding			0
Intrinsic value of options exercisable			$0
Directors [Member] | Non-qualified stock options [Member]
Stockholders Equity [Line Items]
Non-qualified stock options issued to directors	10,000
Options expiration term	7 years
Options exercise price per share	$0.19
2005 Equity Incentive Plan [Member]
Stockholders Equity [Line Items]
Common stock reserved for issuance			283,058
2005 Equity Incentive Plan [Member] | Directors, Officers and Chief Medical Advisor [Member]
Stockholders Equity [Line Items]
Common stock warrants, issued	1,125,000	1,457,100
Common stock warrants, term	10 years	10 years
Common stock warrants, exercise price	$0.60	$0.80
Common stock warrants, premium percentage	216.00%	57.00%
Common stock warrants, fair value per share	$0.10

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Available Outstanding Shares for Future Issuance (Detail) (2005 Equity Incentive Plan [Member])	Mar. 31, 2015
2005 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
2005 Equity Incentive Plan, Shares Outstanding	108,250
2005 Equity Incentive Plan, Shares Available for Issuance	174,808

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity under Equity Incentive Plan and Warrants Issued Outside Plan (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options or Warrants, Balance outstanding, Beginning Balance	1,914,906
Number of Options or Warrants, Granted	1,135,000
Number of Options or Warrants, Exercised	0
Number of Options or Warrants, Cancelled	0
Number of Options or Warrants, Cancelled (unvested)	0
Number of Options or Warrants, Expired (vested)	-5,750
Number of Options or Warrants, Balance outstanding, Ending Balance	3,044,156	1,914,906
Number of Options or Warrants, Exercisable, Ending Balance	3,032,656
Weighted Average Exercise Price, Balance outstanding, Beginning Balance	$2.44
Weighted Average Exercise Price, Granted	$0.60
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Cancelled	$0
Weighted Average Exercise Price, Cancelled (unvested)	$0
Weighted Average Exercise Price, Expired (vested)	$14.80
Weighted Average Exercise Price, Balance outstanding, Ending Balance	$1.73	$2.44
Weighted Average Exercise Price, Exercisable, Ending Balance	$1.74
Weighted Average Remaining Contractual Life (in years), Granted	9 years 11 months 23 days
Weighted Average Remaining Contractual Life (in years), Balance	9 years 18 days	8 years 8 months 27 days
Weighted Average Remaining Contractual Life (in years), Exercisable, Ending Balance	9 years 22 days

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Warrant Activity (Detail) (Warrants [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Warrants [Member]
Class of Warrant or Right [Line Items]
Balance outstanding, Beginning, Number of Warrants	873,336
Warrants issued, Number of Warrants	0
Warrants exercised, Number of Warrants	0
Warrants expired, Number of Warrants	-112,500
Warrants cancelled, Number of Warrants	0
Balance outstanding, Ending, Number of Warrants	760,836	873,336
Warrants exercisable at March 31, 2015, Number of Warrants	760,836
Balance outstanding, Beginning, Weighted Average Exercise Price	$17.79
Warrants issued, Weighted Average Exercise Price	$0
Warrants exercised, Weighted Average Exercise Price	$0
Warrants expired, Weighted Average Exercise Price	$35.40
Warrants cancelled, Weighted Average Exercise Price	$0
Balance outstanding, Ending, Weighted Average Exercise Price	$15.19	$17.79
Warrants exercisable at March 31, 2015, Weighted Average Exercise Price	$15.19
Balance outstanding, Weighted Average Remaining Contractual Life (in years)	11 months 9 days	1 year 22 days
Warrants exercisable at March 31, 2015, Weighted Average Remaining Contractual Life (in years)	11 months 9 days

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (Biorasi LLC [Member], USD $)	1 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2014
Biorasi LLC [Member]
Loss Contingencies [Line Items]
Complaint filed seeking payments related to clinical trial	$0.50

Subsequent_Events_Additional_i

Subsequent Events - Additional information (Detail) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Apr. 06, 2015	Apr. 08, 2015	Apr. 04, 2015	Apr. 03, 2015	Feb. 21, 2014
		Renewals	Tranches	Tranches
Subsequent Event [Line Items]
Ownership percentage, as on the date						27.50%
Shenzhen Qianhai Taxus [Member]
Subsequent Event [Line Items]
Business acquisition, date of agreement	4-Apr-15
Subsequent Events [Member]
Subsequent Event [Line Items]
License period		10 years
License renewal period		5 years
Number of license renewals		2
Subsequent Events [Member] | Latin America [Member]
Subsequent Event [Line Items]
Number of other countries that have right of license to sell		32
Subsequent Events [Member] | Shenzhen Qianhai Taxus [Member]
Subsequent Event [Line Items]
Acquired percentage of outstanding common stock			15.00%	15.00%
Business acquisition, purchase price			3,000,000	3,000,000
Business acquisition, shares issued			$600,000
Business acquisition, share price			$5
Number of tranches payable			3	3
Payment for business acquisition			600,000	600,000
Subsequent Events [Member] | Chief Financial Officer [Member]
Subsequent Event [Line Items]
Severance payments					$0